氟哌利多用于急诊环境中儿童急性躁动的有效性与安全性:一项系统评价
该研究系统评价了胃肠外氟哌利多用于≤21岁儿童急性躁动的有效性与安全性,纳入6篇文献(2篇院前、1篇急诊科、3篇住院),包括1项前瞻性观察研究、3项回顾性观察研究和2篇病例报告。最大样本研究报告达镇静的中位时间为14分钟(四分位距10-20分钟),其他研究均≤15分钟;8%-22%的患者因持续躁动需追加一剂药物。最常见不良反应为肌张力障碍反应和一过性低血压,各1例出现QTc延长和呼吸抑制,但均有显著合并症。结论认为氟哌利多可能有效且安全,但研究设计存在偏倚风险限制了证据强度。
要点
- 最大样本研究报告达镇静的中位时间为14分钟(四分位距10-20分钟),其他研究报告达镇静时间≤15分钟。
- 各研究中8%-22%的患者因持续躁动需追加第二剂药物。
- 最常见不良反应为肌张力障碍反应和一过性低血压;1例QTc延长和1例呼吸抑制,均有显著合并症可能参与。
- 纳入研究偏倚风险为中等至严重,证据受研究设计限制。
适用人群与场景
- ≤21岁儿童,急性严重躁动,就诊于急性护理环境(院前、急诊科或住院部)。
研究设计与关键结果
- 系统评价纳入6篇文献:2篇院前、1篇急诊科、3篇住院;研究类型为1项前瞻性观察研究、3项回顾性观察研究和2篇病例报告。
- 最大样本研究报告达镇静的中位时间为14分钟(四分位距10-20分钟);其他研究报告达镇静时间≤15分钟。
- 各研究中8%-22%的患者因持续躁动需追加第二剂药物。
- 最常见不良反应为肌张力障碍反应和一过性低血压;1例QTc延长和1例呼吸抑制,均有显著合并症可能参与。
- 纳入研究的偏倚风险为中等至严重。
证据类型、等级与局限
- 证据类型:系统评价,纳入随机对照试验、观察性研究和病例系列/报告。
- 偏倚风险:中等至严重。
- 局限:研究设计可能引入偏倚;证据有限。
对床旁实践的改变
- 作者认为,现有数据提示氟哌利多对儿童急性严重躁动可能有效且安全,但受研究设计偏倚风险限制。
- 原研究未给出具体用药剂量、给药途径或推荐等级。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Agitation in children in acute care settings poses significant patient and staff safety concerns. While behavioral approaches are central to reducing agitation and oral medications are preferred, parenteral medications are used when necessary to promote safety. The goal of this systematic review was to evaluate the effectiveness and safety of an ultra-short-acting parenteral medication, droperidol, for the management of acute, severe agitation in children in acute care settings.
METHODS: A systematic review of randomized controlled trials, observational studies, and case series/reports examined the effectiveness and safety of parenteral droperidol for management of acute agitation in patients ≤21 years old in acute care settings. Effectiveness outcomes included time to sedation and need for a subsequent dose of medication. Safety outcomes were adverse effects such as QTc prolongation, hypotension, respiratory depression, and dystonic reactions.
RESULTS: A total of 431 unique articles were identified. Six articles met inclusion criteria: two in the prehospital setting, one in the emergency department, and three in the inpatient hospital setting. The articles included a prospective observational study, three retrospective observational studies, and two case reports. The largest study reported a median time to sedation of 14 min (interquartile range 10-20 min); other studies reported a time to sedation of 15 min or less. Across studies, 8%-22% of patients required a second dose of medication for ongoing agitation. The most frequent adverse effects were dystonic reactions and transient hypotension. One patient had QTc prolongation and another developed respiratory depression, but both had significant comorbidities that may have contributed. The risk of bias in included studies ranged from moderate to critical.
CONCLUSIONS: Existing data on droperidol for management of acute agitation in children suggest that droperidol is both effective and safe for acute, severe agitation in children. Data are limited by study designs that may introduce bias.
参考来源
- Ramsden SC, Pergjika A, Janssen AC, et al. A systematic review of the effectiveness and safety of droperidol for pediatric agitation in acute care settings. Acad Emerg Med. 2022. PMID: 35490341. doi:10.1111/acem.14515
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。